ストックスクリーナーアプリを入手
21.81
8.35%
1.68
プレマーケット:
23.07
1.26
+5.78%
前日終値:
$20.13
開ける：
$20.35
24時間の取引高:
349.57K
Relative Volume:
1.36
時価総額：
$384.18M
収益：
$116.88M
当期純損益:
$-25.09M
株価収益率:
-155.79
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
+30.68%
1か月 パフォーマンス:
+27.62%
6か月 パフォーマンス:
+125.78%
1年 パフォーマンス:
+60.37%
1日の値動き範囲:
$19.58
$21.83
1週間の範囲:
$17.10
$21.83
52週間の値動き範囲:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
21.81 | 384.18M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-03 | 再開されました | Piper Sandler | Neutral |
| 2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 開始されました | B. Riley Securities | Neutral |
| 2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 再開されました | JP Morgan | Overweight |
| 2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 開始されました | Citigroup | Buy |
| 2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 再開されました | Piper Jaffray | Overweight |
| 2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 再開されました | H.C. Wainwright | Buy |
| 2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
| 2016-07-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-13 | 開始されました | Piper Jaffray | Overweight |
| 2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 繰り返されました | Stifel | Buy |
| 2012-11-29 | 開始されました | UBS | Neutral |
| 2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
| 2012-03-26 | 開始されました | Canaccord Genuity | Hold |
| 2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Cantor Fitzgerald Forecasts RIGL FY2025 Earnings - MarketBeat
JW Pharmaceutical gains approval for immune thrombocytopenia treatment TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Long Term Trading Analysis for (RIGL) - Stock Traders Daily
KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel PharmaceuticalsCHOSUNBIZ - 조선비즈
Assenagon Asset Management S.A. Sells 30,987 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Barclays PLC Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Short Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1% - MarketBeat
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Rigel (RIGL) Upgraded to Buy: Here's Why - MSN
Equities Analysts Set Expectations for RIGL Q4 Earnings - MarketBeat
Rigel Pharmaceuticals Seeks for Acquisitions -January 16, 2025 at 11:15 am EST - Marketscreener.com
Cantor Fitzgerald Has Positive View of RIGL FY2024 Earnings - MarketBeat
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Rigel forecasts revenue growth in 2025, reports Q4 sales - Investing.com India
RIGLRigel Pharmaceuticals Inc. (New) Latest Stock News & Market Updates - StockTitan
Rigel Pharmaceuticals sets 2025 sales outlook above estimates - MSN
Rigel forecasts revenue growth in 2025, reports Q4 sales By Investing.com - Investing.com South Africa
Rigel Provides Business Update and 2025 Outlook - PR Newswire
Rigel Pharma Revenue Soars as TAVALISSE Hits $100M Sales Milestone, Sets Ambitious 2025 Targets - StockTitan
(RIGL) Technical Data - Stock Traders Daily
Rigel announces R289 granted Orphan Drug designation by FDA for MDS - TipRanks
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289 - MarketWatch
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire
Rigel's MDS Drug R289 Receives FDA Orphan Drug Status, Boosting Market Exclusivity Potential - StockTitan
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Confe - GuruFocus.com
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
Jane Street Group LLC Lowers Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Malaysian Reserve
Brokerages Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $36.20 - MarketBeat
Rigel Pharma expects to complete workforce reduction by Dec 15 - Reuters
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents (NASDAQ:RIGL) - Seeking Alpha
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St
Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
(RIGL) Trading Signals - Stock Traders Daily
Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St
Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail
Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve
Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat
Rigel Pharmaceuticals announces initial data from Phase 1b study of R289 - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):